Should I Buy BIO? BIO 2026 Analysis

Should You Buy Bio Rad Laboratories Inc (BIO) Today? Analysis, Price Targets, and 2026 Outlook.

Conclusion

Hold

Latest Price

294.910

1 Day change

-1.63%

52 Week Range

368.650

Analysis Updated At

2026/01/28

Not a good buy right now for a beginner long-term investor. Despite being near support (potential short-term bounce setup) and having upside vs. Wall Street targets, BIO’s latest reported quarter shows a sharp deterioration in profitability (large net loss, negative EPS, and weaker gross margin). With no proprietary buy signals today and options open-interest skew leaning defensive, the risk/reward for an impatient long-term entry is not attractive at this moment. Best call: HOLD (do not add new money today).

Technical Analysis

Price/Trend: BIO is trading at 297.7, sitting just above S1 support (296.915) and below the pivot (309.136), which keeps the near-term bias bearish-to-neutral. Momentum: MACD histogram is negative (-2.478) but “negatively contracting,” which often signals downside momentum is fading (possible stabilization), not a confirmed reversal. RSI: RSI_6 at ~27.6 indicates oversold conditions (even though the feed labels it “neutral”), which can support a short-term bounce—but oversold alone is not a reliable long-term entry trigger. Moving averages: Converging MAs suggest consolidation rather than a clear uptrend. Levels to watch: Immediate support 296.9 then 289.4. Resistance/pivot zone 309.1; further resistance 321.4 and 328.9. **Intellectia Proprietary Trading Signals** - [AI Stock Picker](module://ai_stock_pick): No signal on given stock today. - [SwingMax](module://swingmax): No signal on given stock recently.

Options Data

Bearish

Open Interest Put-Call Ratio

Bullish

Option Volume Put-Call Ratio

Positioning/Sentiment: Open Interest Put-Call Ratio at 2.26 is notably put-heavy, typically read as defensive positioning/hedging and a bearish-to-cautious medium-term sentiment signal. Flow Today: Option Volume Put-Call Ratio at 0.01 is extremely call-volume skewed (calls 98 vs puts 1), suggesting today’s trading flow is opportunistically bullish/speculative. Volatility: 30D IV ~36.6 with IV percentile ~42 (mid-range) and low IV rank (~6.5) implies options are not priced for unusually large moves versus the past year’s range. Net take: Mixed—medium-term positioning looks cautious, but today’s flow leans bullish.

Technical Summary

Sell

Buy

Positive Catalysts

- Oversold technical setup near support (296–289 zone) increases odds of a reflex bounce.

Neutral/Negative Catalysts

- Profitability deterioration in the latest reported quarter: net income and EPS turned sharply negative, which is a major long-term red flag.
- Gross margin declined YoY, pressuring the quality of earnings.
- Price is below the pivot (309) with negative MACD: trend is not confirmed bullish.
- Options open-interest skew (put-heavy) suggests investors are hedging or positioning defensively.
- News provided is primarily about Qiagen (not Bio-Rad); there is no clear BIO-specific positive headline catalyst in the feed right now.

Financial Performance

Latest quarter: 2025/Q3. - Revenue: 653.0M, +0.50% YoY (low growth). - Net Income: -341.9M, down -152.34% YoY (significant deterioration). - EPS: -12.7, down -154.41% YoY. - Gross Margin: 52.5%, down -4.16% YoY. Summary: Top-line growth is minimal while profitability and margins weakened materially—this is not the profile of a clean long-term “buy now” setup for a beginner.

Growth

Profitability

Efficiency

Analyst Ratings and Price Target Trends

Recent trend: Both cited firms raised price targets after Q3 (Citi: 350→375, Buy; Wells Fargo: 265→340, Equal Weight). That’s a modestly positive direction on targets, but ratings are mixed (one Buy vs one neutral). Wall Street pros: Higher peer multiples cited by Citi; margin expansion potential even with muted revenue (Wells). Wall Street cons: Cautious tone on 2026 growth; “flat” expectation implied by Equal Weight stance. Influential/politician activity: No recent congress trading data available; insider trend reported as neutral.

2 Analyst Rating

Wall Street analysts forecast BIO stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for BIO is 357.5 USD with a low forecast of 340 USD and a high forecast of 375 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

1 Buy

1 Hold

0 Sell

Moderate Buy

Current: 299.790

Low

340

Averages

357.5

High

375

Current: 299.790

Low

340

Averages

357.5

High

375

Citi

Buy

maintain

$350 -> $375

AI Analysis

2025-10-30

Reason

Citi

Price Target

$350 -> $375

AI Analysis

2025-10-30

maintain

Buy

Reason

Citi raised the firm's price target on Bio-Rad to $375 from $350 and keeps a Buy rating on the shares. The firm cites higher peer multiples for the target bump post the company's Q3 report.

Wells Fargo

Equal Weight

maintain

$265 -> $340

2025-10-30

Reason

Wells Fargo

Price Target

$265 -> $340

2025-10-30

maintain

Equal Weight

Reason

Wells Fargo raised the firm's price target on Bio-Rad to $340 from $265 and keeps an Equal Weight rating on the shares. The firm says shares of Bio-Rad should be flat on the in-line quarter and stable full year guide. Not surprisingly, Bio-Rad is cautious on 2026 growth prospects, but still expects to deliver margin expansion even on muted revenue growth, Wells adds.

Unlock Full Analyst Thesis， Get the complete breakdown of rating reason for BIO

Unlock Now

BIO Should I Buy

BIO Should I Buy

Should You Buy Bio Rad Laboratories Inc (BIO) Today? Analysis, Price Targets, and 2026 Outlook.

Technical Analysis

Options Data

Technical Summary

Positive Catalysts

Neutral/Negative Catalysts

Financial Performance

Growth

Profitability

Efficiency

Analyst Ratings and Price Target Trends

People Also Watch